This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Generic-Drug Stocks Still Under the Weather

So, why is Mylan (MYL - Get Report) down 37.5% over the last 12 months? Why has Barr Pharmaceuticals (BRL) fallen by 21%?

What's wrong with Par Pharmaceutical (PRX), whose stock is off 36%? And why has Watson Pharmaceuticals (WPI) tumbled by 8.5%?

Many of these 12-month results aren't aberrations. Over the last 24 months, shares of Barr, Mylan and Par fared worse than the S&P 500 and the Amex pharmaceutical index. Watson is is slightly ahead of the S&P 500 and better than the Big Pharma index. Teva surpasses all of them.

Reasons for a Slump

There's no common theme for these sagging stocks, says Brian Laegeler of the independent research firm Morningstar. For Mylan, whose market cap is $3.8 billion, and Barr, whose market cap is $4.6 billion, the stock weakness is tied in part to integrating big acquisitions made in 2006.

"Both were playing catch-up with Teva in size and in establishing a presence in Europe," he says. "Overall, they were taking positive actions."

Shaking off the dilutive effects of their acquisitions and reducing deal-related debt will take some time. "I look for good years for Barr and Mylan in 2009 and 2010," he says.

The biggest drag on Watson's stock was recently removed when the Food and Drug Administration said problems at a manufacturing plant had been fixed. The Florida plant belonged to Andrx, a rival acquired by Watson in 2006. Watson, which now has a market cap of around $3 billion, knew about the problems. Until the FDA gave its approval, the agency had refused to approve new drugs that would be made there.
2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
WPI $85.73 0.00%
NVS $103.18 0.00%
MYL $56.35 0.00%
TEVA $69.07 0.00%
AAPL $122.37 0.00%


Chart of I:DJI
DOW 17,745.98 -5.41 -0.03%
S&P 500 2,108.63 +0.06 0.00%
NASDAQ 5,128.7850 +17.0520 0.33%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs